The Amplifai Solver list · August 2026
Who is already solving MedTechs' challenges?
Top global MedTech corporations tell their stakeholders, in writing, what they struggle with. We read all of it, ranked the fifteen problems that recur, and went looking for the companies already solving them to pitch at MedTech Forum in Singapore.
No fee. No commitment. Withdraw any time.
THE AUDIENCE
The room, described honestly.
The MedTech Forum is APACMed's annual meeting, at Suntec Singapore — the 2027 edition, dates to be confirmed. It is not a startup conference with corporates invited. It is a corporate and regulatory meeting with a stage for innovators on Day 1.
Source: medtechforum.asia/speakers, verified 25 August 2026
2024 delegate mix
Source: MedTech Forum
Day 1 carries the Innovation Stage — "From Pilot to Protocol" 10:00–12:00 and "Funding the Future" 14:00–15:50, including the pitch finals and an awards moment.
Source: medtechforum.asia/program
The working paper
Fifteen challenges. Sixty-two filings. Zero guesswork.
The Fifteen Challenges of Asia-Pacific MedTech is a sixteen-page working paper, issued for peer review in August 2026. It scores 62 companies against fifteen challenges, using nothing but what those companies write in their own regulatory filings. No company is named. No market size is claimed. A “no” required reading the full risk-factor section.
| Rank | Challenge | Recognition |
|---|---|---|
| 1 | Supply Chain De-risking | 98% |
| 2 | Reimbursement & Coverage Compression | 78% |
| 3 | Volume-based procurement and tender economics | 76% |
| 4 | Opaque Distributor Networks | 74% |
| 5 | Portfolio Separation & Regulatory Transfer | 60% |
| 6 | Regulatory Fragmentation | 58% |
| 7 | Product Quality, Recalls & Regulatory Enforcement | 56% |
| 8 | ESG & Sustainability Mandates | 56% |
| 9 | Strict Data Localization | 53% |
| 10 | Connected-Device Cybersecurity & Product Security | 53% |
| 11 | Post-Op Home Care Tracking | 43% |
| 12 | Value-Based Healthcare Pivot | 33% |
| 13 | Counterfeiting & Parallel Imports | 33% |
| 14 | Clinician Shortages & Training | 32% |
| 15 | Equipment Maintenance Downtime | 19% |
Representation matrix
“Represented at the Forum” is eleven different things. Pick the ones you want.
Free — virtual representation
Verified profile in the Innovator App, visible to Forum participants for the duration of the programme
Opt-in — only if you tick it
Name and logo in the Solver roster shown on screen at the Day-1 Innovation Stage between sessions
Opt-in — only if you tick it
Name and logo in the printed Solver roster handout distributed at the Startup Zone
Opt-in — only if you tick it
Named from the stage during the Day-1 roster read-out
Opt-in — only if you tick it
Listed on the public Solver page at amp-lif-ai.com
Notify-and-object — listed unless you object
Included in the Solver roster shared with Partner organisations ahead of the Forum
Opt-in — only if you tick it
Shown to a Partner as a challenge-matched candidate when they ask. Introductions remain separate and double opt-in — nothing here shares your contact details
Opt-in — only if you tick it
A short description or named quote you write, used in Amplifai materials
Opt-in — only if you tick it
Reciprocal social promotion — we name you in a LinkedIn post and tag your page, and we send you a ready-made card and caption to post yourself. See §S7
Opt-in — only if you tick it
Included in the Amplifai media list for any Forum press activity
Opt-in — only if you tick it
Your entry in the Amplifai section of the event app
Opt-in — only if you tick it
Pitch slots
Twelve slots. Three minutes each. Decided on evidence.
The Day-1 Innovation Stage has twelve pitch slots of three minutes. There is no fee to apply, buying something does not improve your chances, and the rubric that decides it is published in full before applications open.
Five things get you scored at all: a verifiable entity, a business you are still in, clear governance, disclosed ownership, and a recorded consent. A corporate or investor shareholder does not exclude you — concealing one does. A business unit of a larger company may apply, provided the parent is named.
Then 100 points across five dimensions. Evidence carries the most weight, at 25. Challenge fit is 20, Asia-Pacific relevance 20, readiness to transact 15, and what the room learns 20.
Ties are broken by evidence first, then by challenge coverage — a challenge nobody else is covering beats a stronger field in a crowded one. A package is never a tie-breaker.
Two reviewers score independently and do not see what you have bought. A sponsor may not review. Scores are never published, and nobody is ranked publicly against anybody else.
Twelve slots against a roster of more than a hundred listed companies is a competitive process. We would rather you knew the odds and applied anyway.
Stage, pitch and plenary slots are decided on merit against a published rubric. A package determines which slots you may apply for, never which you win.
Consent
Two minutes. It costs nothing, commits you to nothing, and you can withdraw at any time.
Not an endorsement
Amplifai recommends no supplier. Being listed as a Solver is not an endorsement by Amplifai, by APACMed or by any of its members, and does not indicate that any member has evaluated, selected or bought from your company.
Not a contract
Confirming consent does not create any obligation to buy anything, to attend, to pay a fee, or to continue. You may withdraw at any time by writing to hello@amp-lif-ai.com, and we will remove your listing at the next publication cycle.
Work email only
We can only confirm a listing from a company address, because the address is what proves you speak for the company.
How the roster is built
Nine tests. Every company passes all of them.
The roster is built from research, not applications. Every company on it has been checked against the same nine tests — three hard bars, two strengtheners, two descriptive, and two disclosed.
Acquired, majority-owned or a subsidiary.
Informational; affiliation logged. Not a bar from 25 Aug 2026 — disclosed, never excluded.
The company does not exist, is struck off, or could not be substantiated.
Off the app, retained here.
Exited the business the challenge is about.
Off the app, retained here.
Fraud findings, restatements, litigation or loss of founder control.
Off the app, retained here.
No demonstrated hospital, health-system, payer or device-manufacturer customer. MedTech relevance is inferred.
Marked, retained.
Headquartered outside Asia-Pacific.
Not a problem, marked.
No stated APAC office, engagement or delivery presence.
Not a problem, marked.
An ownership or scale claim could not be substantiated from a primary source.
Marked, retained. Do not publish the claim.
Introducing this solver could put a member's own distributor inside its project.
Must be disclosed first.
Open mode
Not on the list? Make the case.
The roster is built from research, not applications. That does not make it closed — it makes the bar explicit. Tell us which of the fifteen you solve and show us it works somewhere.
Informational; affiliation logged. Not a bar from 25 Aug 2026 — disclosed, never excluded.
Refer
Not the right person? Tell us who is.
Consent for a listing usually sits with a founder, a commercial lead or whoever signs partnership agreements. If that is not you, the fastest thing you can do is name them.
Or forward this instead.
Copy a short forwarding note — a button that copies four sentences and the tokenised link to the clipboard, so the referrer sends it from their own mailbox. A forwarded introduction converts better than a cold one and creates no third-party data obligation at all.
Promotion pack
Tell your side of it.
You have just been named against a challenge that 76% of Asia-Pacific MedTech companies write into their own filings. That is worth a post, and we have done the work.
We will name you in a LinkedIn post before the Forum and tag your page. You are not required to post anything, and nothing here changes if you do not.
NAMED AS A SOLVER
{Legal entity name}
{Canon challenge title}
Named as a risk in {NN}% of 62 Asia-Pacific MedTech filings
Source: Amplifai Working Paper v1.0, August 2026 — 62 regulatory filings read in full
Lockup: Amplifai + The MedTech Forum 2027